<?xml version="1.0" encoding="UTF-8"?>
<p>Drug repositioning, repurposing, reprofiling or re-tasking is the evaluation of existing drugs for new therapeutic purposes.
 <xref rid="B37" ref-type="bibr">
  <sup>37</sup>
 </xref> A candidate drug (investigational or approved) for repurposing efforts already has a known safety and toxicity profile, based on at least successful Phase I or Phase II clinical trials.
 <xref rid="B38" ref-type="bibr">
  <sup>38</sup>
 </xref> Considering the whole process, costs of bringing a repurposed drug to the market have been estimated to be ten times lower and the time is shortened by around a half, compared with a new drug.
 <xref rid="B38" ref-type="bibr">
  <sup>38</sup>
 </xref> Even though the clinical phase III and regulatory aspects remain similar for developing a new drug, drug repurposing possesses many advantages over developing a new drug from scratch: the reduced time and financial investment for development, the lower risk of failure and a consolidated pharmaceutical supply chain for production and distribution to the patients that effectively need treatment.
 <xref rid="B39" ref-type="bibr">
  <sup>39</sup>
 </xref>
</p>
